Features of the appointment of the Trinomia® polypill in patients of different ages | Ukrainian Medical Journal

The effectiveness of secondary prevention of atherosclerotic cardiovascular diseases is largely determined by the level of compliance, which remains suboptimal in real clinical practice. Multifactorial barriers — from comorbid polypharmacy in geriatric patients to behavioral low adherence in people of working age — require the implementation of innovative strategies to simplify pharmacotherapy. Purpose of the work: to systematize evidence on the clinical effectiveness and safety of the use of the Trinomia^® cardiovascular polypill as a basic tool for optimizing long-term prognosis in different age populations. The results of modern multicenter randomized studies (in particular, SECURE and FOCUS) indicate the advantages of a fixed combination of acetylsalicylic acid, atorvastatin and ramipril in reducing the incidence of major adverse cardiovascular events by 24%. In elderly patients, the use of a polypill minimizes iatrogenic risks and dosing errors inherent in complex multicomponent regimens. For young and middle-aged patients, the key factor is increased adherence to asymptomatic therapy, which ensures stable implementation of lipid-lowering and antihypertensive effects. A differentiated approach to initiating therapy with Trinomia^® at the stabilization stage after an acute ischemic event has been identified as a pathogenetically justified and pharmacoeconomically feasible strategy that allows significantly improving survival and quality of life in patients with high cardiovascular risk.

References

1. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484
2. Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024, 45(36), 3415–3537. https://doi.org/10.1093/eurheartj/ehae177
3. Byrne R.A., Rossello X., Coughlan J.J., et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44(38), 3720–3826. https://doi.org/10.1093/eurheartj/ehad191
4. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018, 36, 1953–2041. https://doi.org/10.1093/eurheartj/ehy339
5. Mach F., Koskinas K.C., Roeters van Lennep J.E., et al. 2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025, 409, 120479. https://doi.org/10.1016/j.atherosclerosis.2025.120479
6. NICE (National Institute for Health and Care Excellence). Cardiovascular disease: Risk assessment and reduction, including lipid modification. Clinical guideline [CG181]. 2014. Retrieved from https://www.nice.org.uk/guidance/cg181
7. De la Rosa A., Arrington K., Desai R., et al. Polypill strategy in secondary cardiovascular prevention. Curr Cardiol Rep. 2024, 26(5), 443–450. https://doi.org/10.1007/s11886-024-02046-1
8. Khan A.A., Siddiqui S.A., Yasmin F., et al. The era of polypills in the management of cardiovascular diseases: Are we there yet? Curr Probl Cardiol. 2023, 48(8), 101233. https://doi.org/10.1016/j.cpcardiol.2022.101233
9. Araújo F., Caldeira D., Aguiar C., et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023, 42(10), 861–872. https://doi.org/10.1016/j.repc.2023.02.011
10. Castellano J.M., Sanz G., Peñalvo J.L., et al. A polypill strategy to improve adherence: Results from the FOCUS project. J Am Coll Cardiol. 2014, 64(20), 2071–2082. https://doi.org/10.1016/j.jacc.2014.08.021
11. Castellano J.M., Pocock S.J., Bhatt D.L., et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022, 387(11), 967–977. https://doi.org/10.1056/NEJMoa2208275.
12. Rivera A., Campos B., Ceolin S., et al. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: A meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2023, 30(16), 1828–1837. https://doi.org/10.1093/eurjpc/zwad245
13. Grigorian-Shamagian L., Edel K., Esteve-Pastor M.A., et al. Practical decision algorithms for the use of the cardiovascular polypill in secondary prevention in Europe. Front Cardiovasc Med. 2021, 8, 663361. https://doi.org/10.3389/fcvm.2021.663361
14. Piñeiro D., González-Juanatey J.R., Abreu A., et al. The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) paradigm shift in secondary prevention: Global expert Delphi consensus. Glob Heart. 2025, 20(1), 83. https://doi.org/10.5334/gh.1466
15. González-Juanatey J.R., Mostaza J.M., Lobos J.M., et al. Consensus document for the use of the polypill in the secondary prevention of cardiovascular disease. Med Clin (Barc). 2017, 148(3), 139.e1–139.e15. https://doi.org/10.1016/j.medcli.2016.10.031
16. Thom S., Field J., Poulter N., et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial. Eur J Prev Cardiol. 2014, 21(2), 252–261. https://doi.org/10.1177/2047487312463278
17. Sanz G., Fuster V., Guzmán L., et al. The fixed-dose combination drug for secondary cardiovascular prevention project. Am Heart J. 2011, 162(5), 811–817.e1. https://doi.org/10.1016/j.ahj.2011.08.012
18. Grigorian-Shamagian L., Coca A., Morais J., et al. The use of the CNIC-Polypill in real-life clinical practice. BMC Proc. 2023, 17(Suppl 8), 20. https://doi.org/10.1186/s12919-023-00268-9
19. Marx N., Federici M., Schütt K., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44(39), 4043–4140. https://doi.org/10.1093/eurheartj/ehad192
20. Castellano J.M., Fuster V., Jennings C., et al. Role of the polypill for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol. 2017, 24(3_suppl), 44–51. https://doi.org/10.1177/2047487317707324
21. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J. Human Hypertens. 2004, 18(11), 781–788. https://doi.org/10.1038/sj.jhh.1001748
22. McEvoy J.W., McCarthy C.P., Bruno R.M., et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2025, 45(38), 3912–4018. https://doi.org/10.1093/eurheartj/ehae178
23. Guerrero-Pinedo F., Ochoa-Zárate L., Salazar C.J., et al. Association of traditional cardiovascular risk factors in adults younger than 55 years with coronary heart disease. SAGE Open Med. 2020, 8, 2050312120932703. https://doi.org/10.1177/2050312120932703
24. Tong Z., Xie Y., Li K., et al. The global burden and risk factors of cardiovascular diseases in adolescent and young adults, 1990–2019. BMC Public Health. 2024, 24(1), 1017. https://doi.org/10.1186/s12889-024-18445-6.